<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35203555</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Human Milk Oligosaccharides: Potential Applications in COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">346</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10020346</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has become a global health crisis with more than four million deaths worldwide. A substantial number of COVID-19 survivors continue suffering from long-COVID syndrome, a long-term complication exhibiting chronic inflammation and gut dysbiosis. Much effort is being expended to improve therapeutic outcomes. Human milk oligosaccharides (hMOS) are non-digestible carbohydrates known to exert health benefits in breastfed infants by preventing infection, maintaining immune homeostasis and nurturing healthy gut microbiota. These beneficial effects suggest the hypothesis that hMOS might have applications in COVID-19 as receptor decoys, immunomodulators, mucosal signaling agents, and prebiotics. This review summarizes hMOS biogenesis and classification, describes the possible mechanisms of action of hMOS upon different phases of SARS-CoV-2 infection, and discusses the challenges and opportunities of hMOS research for clinical applications in COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chutipongtanate</LastName><ForeName>Somchai</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6398-5626</Identifier><AffiliationInfo><Affiliation>Pediatric Translational Research Unit, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine Ramathibodi Hospital, Chakri Naruebodindra Medical Institute, Mahidol University, Samut Prakan 10540, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>Ardythe L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newburg</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HMOS</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">mucosal signaling</Keyword><Keyword MajorTopicYN="N">prebiotics</Keyword><Keyword MajorTopicYN="N">receptor binding inhibition</Keyword></KeywordList><CoiStatement>S.C. declares no conflict of interest. A.L.M and D.S.N. own stock in Glycosyn, LLC whose potential value could be influenced should the concept presented herein come to fruition.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35203555</ArticleId><ArticleId IdType="pmc">PMC8961778</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10020346</ArticleId><ArticleId IdType="pii">biomedicines10020346</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet. Infect. Dis. 2021;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409&#x2013;424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahradn&#xed;k J., Marciano S., Shemesh M., Zoler E., Harari D., Chiaravalli J., Meyer B., Rudich Y., Li C., Marton I., et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat. Microbiol. 2021;6:1188&#x2013;1198. doi: 10.1038/s41564-021-00954-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00954-4</ArticleId><ArticleId IdType="pubmed">34400835</ArticleId></ArticleIdList></Reference><Reference><Citation>Subedi L., Tchen S., Gaire B.P., Hu B., Hu K. Adjunctive Nutraceutical Therapies for COVID-19. Int. J. Mol. Sci. 2021;22:1963. doi: 10.3390/ijms22041963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041963</ArticleId><ArticleId IdType="pmc">PMC7920448</ArticleId><ArticleId IdType="pubmed">33669456</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Felten R., Gallais F., Nazon C., Chatelus E., Pijnenburg L., Mengin A., Gras A., Vidailhet P., Arnould-Michel R., et al. Refining &#x201c;Long-COVID&#x201d; by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infect. Dis. Ther. 2021;10:1747&#x2013;1763. doi: 10.1007/s40121-021-00484-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00484-w</ArticleId><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw. Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.-Y., Zhang F., Liu Q., Li A.Y., Chung A.C., Cheung C.P., Tso E.Y., Fung K.S., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gu S., Chen Y., Lu H., Shi D., Guo J., Wu W.-R., Yang Y., Li Y., Xu K.-J., et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2021;71:222&#x2013;225. doi: 10.1136/gutjnl-2021-324090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324090</ArticleId><ArticleId IdType="pmc">PMC8666823</ArticleId><ArticleId IdType="pubmed">33833065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard O., Morrow A.L. Human milk composition: Nutrients and bioactive factors. Pediatr. Clin. N. Am. 2013;60:49&#x2013;74. doi: 10.1016/j.pcl.2012.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcl.2012.10.002</ArticleId><ArticleId IdType="pmc">PMC3586783</ArticleId><ArticleId IdType="pubmed">23178060</ArticleId></ArticleIdList></Reference><Reference><Citation>Horta B.L. Breastfeeding: Investing in the Future. Breastfeed. Med. 2019;14:S11&#x2013;S12. doi: 10.1089/bfm.2019.0032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/bfm.2019.0032</ArticleId><ArticleId IdType="pmc">PMC6486667</ArticleId><ArticleId IdType="pubmed">30985202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y.-J., Yeung C.-Y. Recent advance in infant nutrition: Human milk oligosaccharides. Pediatr. Neonatol. 2021;62:347&#x2013;353. doi: 10.1016/j.pedneo.2020.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pedneo.2020.12.013</ArticleId><ArticleId IdType="pubmed">33893051</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire M.K., Meehan C.L., McGuire M.A., Williams J.E., Foster J., Sellen D.W., Kamau-Mbuthia E.W., Kamundia E.W., Mbugua S., Moore S.E., et al. What&#x2019;s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. Am. J. Clin. Nutr. 2017;105:1086&#x2013;1100. doi: 10.3945/ajcn.116.139980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.116.139980</ArticleId><ArticleId IdType="pmc">PMC5402033</ArticleId><ArticleId IdType="pubmed">28356278</ArticleId></ArticleIdList></Reference><Reference><Citation>Azad M.B., Robertson B., Atakora F., Becker A.B., Subbarao P., Moraes T.J., Mandhane P.J., Turvey S.E., Lefebvre D.L., Sears M.R., et al. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. J. Nutr. 2018;148:1733&#x2013;1742. doi: 10.1093/jn/nxy175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/nxy175</ArticleId><ArticleId IdType="pubmed">30247646</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel T.M., Binia A., de Castro C.A., Thakkar S.K., Billeaud C., Agosti M., Al-Jashi I., Costeira M.J., Marchini G., Mart&#xed;nez-Costa C., et al. Impact of maternal characteristics on human milk oligosaccharide composition over the first 4 months of lactation in a cohort of healthy European mothers. Sci. Rep. 2019;9:11767. doi: 10.1038/s41598-019-48337-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48337-4</ArticleId><ArticleId IdType="pmc">PMC6692355</ArticleId><ArticleId IdType="pubmed">31409852</ArticleId></ArticleIdList></Reference><Reference><Citation>Thum C., Wall C.R., Weiss G.A., Wang W., Szeto I.M.-Y., Day L. Changes in HMO Concentrations throughout Lactation: Influencing Factors, Health Effects and Opportunities. Nutrients. 2021;13:2272. doi: 10.3390/nu13072272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072272</ArticleId><ArticleId IdType="pmc">PMC8308359</ArticleId><ArticleId IdType="pubmed">34209241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode L. Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology. 2012;22:1147&#x2013;1162. doi: 10.1093/glycob/cws074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cws074</ArticleId><ArticleId IdType="pmc">PMC3406618</ArticleId><ArticleId IdType="pubmed">22513036</ArticleId></ArticleIdList></Reference><Reference><Citation>Newburg D.S., Ruiz-Palacios G.M., Morrow A.L. Human milk glycans protect infants against enteric pathogens. Annu. Rev. Nutr. 2005;25:37&#x2013;58. doi: 10.1146/annurev.nutr.25.050304.092553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.nutr.25.050304.092553</ArticleId><ArticleId IdType="pubmed">16011458</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao B., Kellman B.P., Chiang A.W.T., Zhang Y., Sorrentino J.T., York A.K., Mohammad M.A., Haymond M.W., Bode L., Lewis N.E. Correcting for sparsity and interdependence in glycomics by accounting for glycan biosynthesis. Nat. Commun. 2021;12:4988. doi: 10.1038/s41467-021-25183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25183-5</ArticleId><ArticleId IdType="pmc">PMC8371009</ArticleId><ArticleId IdType="pubmed">34404781</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooling L. Blood Groups in Infection and Host Susceptibility. Clin. Microbiol. Rev. 2015;28:801&#x2013;870. doi: 10.1128/CMR.00109-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00109-14</ArticleId><ArticleId IdType="pmc">PMC4475644</ArticleId><ArticleId IdType="pubmed">26085552</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor S.L., McGuckin M.A., Wesselingh S., Rogers G.B. Infection&#x2019;s Sweet Tooth: How Glycans Mediate Infection and Disease Susceptibility. Trends Microbiol. 2018;26:92&#x2013;101. doi: 10.1016/j.tim.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2017.09.011</ArticleId><ArticleId IdType="pmc">PMC7125966</ArticleId><ArticleId IdType="pubmed">29079498</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P., Xia M., Tan M., Zhong W., Wei C., Wang L., Morrow A., Jiang X. Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. J. Virol. 2012;86:4833&#x2013;4843. doi: 10.1128/JVI.05507-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05507-11</ArticleId><ArticleId IdType="pmc">PMC3347384</ArticleId><ArticleId IdType="pubmed">22345472</ArticleId></ArticleIdList></Reference><Reference><Citation>Currier R.L., Payne D.C., Staat M.A., Selvarangan R., Shirley S.H., Halasa N., Boom J.A., Englund J.A., Szilagyi P.G., Harrison C.J., et al. Innate Susceptibility to Norovirus Infections Influenced by FUT2 Genotype in a United States Pediatric Population. Clin. Infect. Dis. 2015;60:1631&#x2013;1638. doi: 10.1093/cid/civ165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ165</ArticleId><ArticleId IdType="pmc">PMC4447782</ArticleId><ArticleId IdType="pubmed">25744498</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne D.C., Currier R.L., Staat M.A., Sahni L.C., Selvarangan R., Halasa N.B., Englund J.A., Weinberg G.A., Boom J.A., Szilagyi P.G., et al. Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA Pediatr. 2015;169:1040&#x2013;1045. doi: 10.1001/jamapediatrics.2015.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2015.2002</ArticleId><ArticleId IdType="pmc">PMC4856001</ArticleId><ArticleId IdType="pubmed">26389824</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton S.J., Murray R., Lillycrop K.A., Inskip H.M., Harvey N.C., Cooper C., Karnani N., Zolezzi I.S., Sprenger N., Godfrey K.M., et al. FUT2 Genetic Variants and Reported Respiratory and Gastrointestinal Illnesses During Infancy. J. Infect. Dis. 2019;219:836&#x2013;843. doi: 10.1093/infdis/jiy582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy582</ArticleId><ArticleId IdType="pmc">PMC6687504</ArticleId><ArticleId IdType="pubmed">30376117</ArticleId></ArticleIdList></Reference><Reference><Citation>Loureiro Tonini M.A., Pires Gon&#xe7;alves Barreira D.M., Bueno de Freitas Santolin L., Bondi Volpini L.P., Gagliardi Leite J.P., Le Moullac-Vaidye B., Le Pendu J., Cruz Spano L. FUT2, Secretor Status and FUT3 Polymorphisms of Children with Acute Diarrhea Infected with Rotavirus and Norovirus in Brazil. Viruses. 2020;12:1084. doi: 10.3390/v12101084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12101084</ArticleId><ArticleId IdType="pmc">PMC7600990</ArticleId><ArticleId IdType="pubmed">32992989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215&#x2013;220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P., Praissman J.L., Grant O.C., Cai Y., Xiao T., Rosenbalm K.E., Aoki K., Kellman B.P., Bridger R., Barouch D.H., et al. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. Cell Host Microbe. 2020;28:586&#x2013;601.e6. doi: 10.1016/j.chom.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7443692</ArticleId><ArticleId IdType="pubmed">32841605</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., Wong S.-K., Huang I.-C., Xu K., Vasilieva N., et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24:1634&#x2013;1643. doi: 10.1038/sj.emboj.7600640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600640</ArticleId><ArticleId IdType="pmc">PMC1142572</ArticleId><ArticleId IdType="pubmed">15791205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdipour A.R., Hummer G. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proc. Natl. Acad. Sci. USA. 2021;118:e2100425118. doi: 10.1073/pnas.2100425118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2100425118</ArticleId><ArticleId IdType="pmc">PMC8126795</ArticleId><ArticleId IdType="pubmed">33903171</ArticleId></ArticleIdList></Reference><Reference><Citation>Golinelli D., Boetto E., Maietti E., Fantini M.P. The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. PLoS ONE. 2020;15:e0239508. doi: 10.1371/journal.pone.0239508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0239508</ArticleId><ArticleId IdType="pmc">PMC7500631</ArticleId><ArticleId IdType="pubmed">32946531</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Zhang T., Ma L., Zhang H., Wang H., Wei W., Pei H., Li H. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2021;48:100785. doi: 10.1016/j.blre.2020.100785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100785</ArticleId><ArticleId IdType="pmc">PMC7834371</ArticleId><ArticleId IdType="pubmed">33309392</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Youha S.A., Alduaij W., Al-Serri A., Almazeedi S.M., Al-Haddad M., Jamal M.H., Shih A.W., Al-Sabah S.K. The impact of ABO blood groups on clinical outcomes and susceptibility to COVID-19: A retrospective study in an unselected population. Transfusion. 2021;61:1631&#x2013;1641. doi: 10.1111/trf.16365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16365</ArticleId><ArticleId IdType="pmc">PMC8250670</ArticleId><ArticleId IdType="pubmed">33682150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankelow T.J., Singleton B.K., Moura P.L., Stevens-Hernandez C.J., Cogan N.M., Gyorffy G., Kupzig S., Nichols L., Asby C., Pooley J., et al. Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications. EJHaem. 2021;2:175&#x2013;187. doi: 10.1002/jha2.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jha2.180</ArticleId><ArticleId IdType="pmc">PMC8176350</ArticleId><ArticleId IdType="pubmed">34124710</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon P., Cl&#xe9;ment M., S&#xe9;bille V., Rivain J.-G., Chou C.-F., Ruvo&#xeb;n-Clouet N., Le Pendu J. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008;18:1085&#x2013;1093. doi: 10.1093/glycob/cwn093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwn093</ArticleId><ArticleId IdType="pmc">PMC7108609</ArticleId><ArticleId IdType="pubmed">18818423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.-C., Arthur C.M., Wang J., Verkerke H., Josephson C.D., Kalman D., Roback J.D., Cummings R.D., Stowell S.R. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021;5:1305&#x2013;1309. doi: 10.1182/bloodadvances.2020003259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003259</ArticleId><ArticleId IdType="pmc">PMC7929867</ArticleId><ArticleId IdType="pubmed">33656534</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Huang P., Zhong W., Tan M., Farkas T., Morrow A.L., Newburg D.S., Ruiz-Palacios G.M., Pickering L.K. Human milk contains elements that block binding of noroviruses to human histo-blood group antigens in saliva. J. Infect. Dis. 2004;190:1850&#x2013;1859. doi: 10.1086/425159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/425159</ArticleId><ArticleId IdType="pubmed">15499543</ArticleId></ArticleIdList></Reference><Reference><Citation>Koromyslova A., Tripathi S., Morozov V., Schroten H., Hansman G.S. Human norovirus inhibition by a human milk oligosaccharide. Virology. 2017;508:81&#x2013;89. doi: 10.1016/j.virol.2017.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2017.04.032</ArticleId><ArticleId IdType="pubmed">28505592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch F.-G., Hansman G.S., Morozov V., Kunz C., Schroten H. Avidity of &#x3b1;-fucose on human milk oligosaccharides and blood group-unrelated oligo/polyfucoses is essential for potent norovirus-binding targets. J. Biol. Chem. 2018;293:11955&#x2013;11965. doi: 10.1074/jbc.RA117.001369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA117.001369</ArticleId><ArticleId IdType="pmc">PMC6066315</ArticleId><ArticleId IdType="pubmed">29858242</ArticleId></ArticleIdList></Reference><Reference><Citation>Weichert S., Koromyslova A., Singh B.K., Hansman S., Jennewein S., Schroten H., Hansman G.S. Structural Basis for Norovirus Inhibition by Human Milk Oligosaccharides. J. Virol. 2016;90:4843&#x2013;4848. doi: 10.1128/JVI.03223-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03223-15</ArticleId><ArticleId IdType="pmc">PMC4836343</ArticleId><ArticleId IdType="pubmed">26889023</ArticleId></ArticleIdList></Reference><Reference><Citation>Derya S.M., Spiegel H., Hanisch F.-G., Morozov V., Schroten H., Jennewein S., Parschat K. Biotechnologically produced fucosylated oligosaccharides inhibit the binding of human noroviruses to their natural receptors. J. Biotechnol. 2020;318:31&#x2013;38. doi: 10.1016/j.jbiotec.2020.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2020.05.001</ArticleId><ArticleId IdType="pubmed">32387450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hester S.N., Chen X., Li M., Monaco M.H., Comstock S.S., Kuhlenschmidt T.B., Kuhlenschmidt M.S., Donovan S.M. Human milk oligosaccharides inhibit rotavirus infectivity in vitro and in acutely infected piglets. Br. J. Nutr. 2013;110:1233&#x2013;1242. doi: 10.1017/S0007114513000391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114513000391</ArticleId><ArticleId IdType="pubmed">23442265</ArticleId></ArticleIdList></Reference><Reference><Citation>Laucirica D.R., Triantis V., Schoemaker R., Estes M.K., Ramani S. Milk Oligosaccharides Inhibit Human Rotavirus Infectivity in MA104 Cells. J. Nutr. 2017;147:1709&#x2013;1714. doi: 10.3945/jn.116.246090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.116.246090</ArticleId><ArticleId IdType="pmc">PMC5572490</ArticleId><ArticleId IdType="pubmed">28637685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozalbo-Rovira R., Ciges-Tomas J.R., Vila-Vicent S., Buesa J., Santiso-Bell&#xf3;n C., Monedero V., Yebra M.J., Marina A., Rodr&#xed;guez-D&#xed;az J. Unraveling the role of the secretor antigen in human rotavirus attachment to histo-blood group antigens. PLoS Pathog. 2019;15:e1007865. doi: 10.1371/journal.ppat.1007865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007865</ArticleId><ArticleId IdType="pmc">PMC6609034</ArticleId><ArticleId IdType="pubmed">31226167</ArticleId></ArticleIdList></Reference><Reference><Citation>Naarding M.A., Ludwig I.S., Groot F., Berkhout B., Geijtenbeek T.B.H., Pollakis G., Paxton W.A. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J. Clin. Investig. 2005;115:3256&#x2013;3264. doi: 10.1172/JCI25105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25105</ArticleId><ArticleId IdType="pmc">PMC1257537</ArticleId><ArticleId IdType="pubmed">16239964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong P., Ninonuevo M.R., Lee B., Lebrilla C., Bode L. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) Br. J. Nutr. 2009;101:482&#x2013;486. doi: 10.1017/S0007114508025804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114508025804</ArticleId><ArticleId IdType="pubmed">19230080</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey R.P., Kim D.H., Woo J., Song J., Jang S.H., Kim J.B., Cheong K.M., Oh J.S., Sohng J.K. Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: In vivo assessment of 3&#x2032;-sialyllactose against H9N2 in chickens. Sci. Rep. 2018;8:2563. doi: 10.1038/s41598-018-20955-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20955-4</ArticleId><ArticleId IdType="pmc">PMC5803236</ArticleId><ArticleId IdType="pubmed">29416087</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;nther S.C., Maier J.D., Vetter J., Podvalnyy N., Khanzhin N., Hennet T., Stertz S. Antiviral potential of 3&#x2032;-sialyllactose- and 6&#x2032;-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses. Sci. Rep. 2020;10:768. doi: 10.1038/s41598-020-57608-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57608-4</ArticleId><ArticleId IdType="pmc">PMC6972948</ArticleId><ArticleId IdType="pubmed">31964943</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P., Farkas T., Zhong W., Tan M., Thornton S., Morrow A.L., Jiang X. Norovirus and histo-blood group antigens: Demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 2005;79:6714&#x2013;6722. doi: 10.1128/JVI.79.11.6714-6722.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.11.6714-6722.2005</ArticleId><ArticleId IdType="pmc">PMC1112114</ArticleId><ArticleId IdType="pubmed">15890909</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Hulswit R.J.G., Widjaja I., Raj V.S., McBride R., Peng W., Widagdo W., Tortorici M.A., van Dieren B., Lang Y., et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl. Acad. Sci. USA. 2017;114:E8508&#x2013;E8517. doi: 10.1073/pnas.1712592114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1712592114</ArticleId><ArticleId IdType="pmc">PMC5635925</ArticleId><ArticleId IdType="pubmed">28923942</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd-Leotis L., Lasanajak Y., Bowen T., Baker K., Song X., Suthar M.S., Cummings R.D., Steinhauer D.A. SARS-CoV-2 and other coronaviruses bind to phosphorylated glycans from the human lung. Virology. 2021;562:142&#x2013;148. doi: 10.1016/j.virol.2021.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2021.07.012</ArticleId><ArticleId IdType="pmc">PMC8299723</ArticleId><ArticleId IdType="pubmed">34325286</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., Uhl S., Hoagland D., M&#xf8;ller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036&#x2013;1045.e9. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Saichi M., Ladjemi M.Z., Korniotis S., Rousseau C., Ait Hamou Z., Massenet-Regad L., Amblard E., Noel F., Marie Y., Bouteiller D., et al. Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. Nat. Cell Biol. 2021;23:538&#x2013;551. doi: 10.1038/s41556-021-00681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-021-00681-2</ArticleId><ArticleId IdType="pubmed">33972731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wack A. Monocyte and dendritic cell defects in COVID-19. Nat. Cell Biol. 2021;23:445&#x2013;447. doi: 10.1038/s41556-021-00685-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-021-00685-y</ArticleId><ArticleId IdType="pubmed">33972732</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cevins C., Luka M., Smith N., Meynier S., Mag&#xe9;rus A., Carbone F., Garc&#xed;a-Paredes V., Barnabei L., Batignes M., Boull&#xe9; A., et al. A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis. Med (N. Y.) 2021;2:1072&#x2013;1092.e7. doi: 10.1016/j.medj.2021.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.08.002</ArticleId><ArticleId IdType="pmc">PMC8363470</ArticleId><ArticleId IdType="pubmed">34414385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., P&#xe9;r&#xe9; H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Wijst M.G.P., Vazquez S.E., Hartoularos G.C., Bastard P., Grant T., Bueno R., Lee D.S., Greenland J.R., Sun Y., Perez R., et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 2021;13:eabh2624. doi: 10.1126/scitranslmed.abh2624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C.-Y., Xu J., He J.-Q., Lu Y.-Q. Immune dysfunction following COVID-19, especially in severe patients. Sci. Rep. 2020;10:15838. doi: 10.1038/s41598-020-72718-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72718-9</ArticleId><ArticleId IdType="pmc">PMC7522270</ArticleId><ArticleId IdType="pubmed">32985562</ArticleId></ArticleIdList></Reference><Reference><Citation>Newburg D.S., He Y. Neonatal Gut Microbiota and Human Milk Glycans Cooperate to Attenuate Infection and Inflammation. Clin. Obstet. Gynecol. 2015;58:814&#x2013;826. doi: 10.1097/GRF.0000000000000156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GRF.0000000000000156</ArticleId><ArticleId IdType="pubmed">26457857</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan S.M., Comstock S.S. Human Milk Oligosaccharides Influence Neonatal Mucosal and Systemic Immunity. Ann. Nutr. Metab. 2016;69((Suppl. S2)):42&#x2013;51. doi: 10.1159/000452818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452818</ArticleId><ArticleId IdType="pmc">PMC6392703</ArticleId><ArticleId IdType="pubmed">28103609</ArticleId></ArticleIdList></Reference><Reference><Citation>Comstock S.S., Wang M., Hester S.N., Li M., Donovan S.M. Select human milk oligosaccharides directly modulate peripheral blood mononuclear cells isolated from 10-d-old pigs. Br. J. Nutr. 2014;111:819&#x2013;828. doi: 10.1017/S0007114513003267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114513003267</ArticleId><ArticleId IdType="pubmed">24131853</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiwegger T., Stahl B., Haidl P., Schmitt J., Boehm G., Dehlink E., Urbanek R., Sz&#xe9;pfalusi Z. Prebiotic oligosaccharides: In vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatr. Allergy Immunol. 2010;21:1179&#x2013;1188. doi: 10.1111/j.1399-3038.2010.01062.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3038.2010.01062.x</ArticleId><ArticleId IdType="pubmed">20444147</ArticleId></ArticleIdList></Reference><Reference><Citation>Velupillai P., Harn D.A. Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: A mechanism for regulation of CD4+ T-cell subsets. Proc. Natl. Acad. Sci. USA. 1994;91:18&#x2013;22. doi: 10.1073/pnas.91.1.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.1.18</ArticleId><ArticleId IdType="pmc">PMC42877</ArticleId><ArticleId IdType="pubmed">7904066</ArticleId></ArticleIdList></Reference><Reference><Citation>Atochina O., Harn D. LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction. Clin. Diagn. Lab. Immunol. 2005;12:1041&#x2013;1049. doi: 10.1128/CDLI.12.9.1041-1049.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.12.9.1041-1049.2005</ArticleId><ArticleId IdType="pmc">PMC1235802</ArticleId><ArticleId IdType="pubmed">16148169</ArticleId></ArticleIdList></Reference><Reference><Citation>Atochina O., Da&#x2019;dara A.A., Walker M., Harn D.A. The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. Immunology. 2008;125:111&#x2013;121. doi: 10.1111/j.1365-2567.2008.02826.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02826.x</ArticleId><ArticleId IdType="pmc">PMC2526265</ArticleId><ArticleId IdType="pubmed">18373667</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L., van De Worp W.R., Stassen R., van Maastrigt C., Kettelarij N., Stahl B., Blijenberg B., Overbeek S.A., Folkerts G., Garssen J., et al. Human milk oligosaccharides promote immune tolerance via direct interactions with human dendritic cells. Eur. J. Immunol. 2019;49:1001&#x2013;1014. doi: 10.1002/eji.201847971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847971</ArticleId><ArticleId IdType="pmc">PMC6619030</ArticleId><ArticleId IdType="pubmed">30900752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayechu-Muruzabal V., Overbeek S.A., Kostadinova A.I., Stahl B., Garssen J., Van&#x2019;t Land B., Willemsen L.E.M. Exposure of Intestinal Epithelial Cells to 2&#x2032;-Fucosyllactose and CpG Enhances Galectin Release and Instructs Dendritic Cells to Drive Th1 and Regulatory-Type Immune Development. Biomolecules. 2020;10:784. doi: 10.3390/biom10050784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10050784</ArticleId><ArticleId IdType="pmc">PMC7278199</ArticleId><ArticleId IdType="pubmed">32438601</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P.G., Carter M.R., Atochina O., Da&#x2019;Dara A.A., Piskorska D., McGuire E., Harn D.A. Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism. J. Immunol. 2003;171:5837&#x2013;5841. doi: 10.4049/jimmunol.171.11.5837.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.11.5837</ArticleId><ArticleId IdType="pubmed">14634093</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Lawlor N.T., Newburg D.S. Human Milk Components Modulate Toll-like Receptor-Mediated Inflammation. Adv. Nutr. 2016;7:102&#x2013;111. doi: 10.3945/an.115.010090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.115.010090</ArticleId><ArticleId IdType="pmc">PMC4717889</ArticleId><ArticleId IdType="pubmed">26773018</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W., Rice C.M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 2011;1:519&#x2013;525. doi: 10.1016/j.coviro.2011.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.10.008</ArticleId><ArticleId IdType="pmc">PMC3274382</ArticleId><ArticleId IdType="pubmed">22328912</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J.R. Type I interferons in viral control and immune regulation. Curr. Opin. Virol. 2016;16:31&#x2013;40. doi: 10.1016/j.coviro.2016.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.01.001</ArticleId><ArticleId IdType="pmc">PMC4821698</ArticleId><ArticleId IdType="pubmed">26812607</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosse K.M., Monson E.A., Beard M.R., Helbig K.J. Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling. J. Innate Immun. 2018;10:85&#x2013;93. doi: 10.1159/000484258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484258</ArticleId><ArticleId IdType="pmc">PMC5969054</ArticleId><ArticleId IdType="pubmed">29186718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bencze D., Fekete T., P&#xe1;zm&#xe1;ndi K. Type I Interferon Production of Plasmacytoid Dendritic Cells under Control. Int. J. Mol. Sci. 2021;22:4190. doi: 10.3390/ijms22084190.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084190</ArticleId><ArticleId IdType="pmc">PMC8072550</ArticleId><ArticleId IdType="pubmed">33919546</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendi G.A., Coviello S., Bhat N., Zea-Hernandez J., Ferolla F.M., Polack F.P. Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus. Acta Paediatr. 2010;99:1517&#x2013;1521. doi: 10.1111/j.1651-2227.2010.01862.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1651-2227.2010.01862.x</ArticleId><ArticleId IdType="pmc">PMC5454496</ArticleId><ArticleId IdType="pubmed">20456265</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassilopoulou E., Feketea G., Koumbi L., Mesiari C., Berghea E.C., Konstantinou G.N. Breastfeeding and COVID-19: From Nutrition to Immunity. Front. Immunol. 2021;12:661806. doi: 10.3389/fimmu.2021.661806.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.661806</ArticleId><ArticleId IdType="pmc">PMC8058436</ArticleId><ArticleId IdType="pubmed">33897707</ArticleId></ArticleIdList></Reference><Reference><Citation>Comstock S.S., Li M., Wang M., Monaco M.H., Kuhlenschmidt T.B., Kuhlenschmidt M.S., Donovan S.M. Dietary Human Milk Oligosaccharides but Not Prebiotic Oligosaccharides Increase Circulating Natural Killer Cell and Mesenteric Lymph Node Memory T Cell Populations in Noninfected and Rotavirus-Infected Neonatal Piglets. J. Nutr. 2017;147:1041&#x2013;1047. doi: 10.3945/jn.116.243774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.116.243774</ArticleId><ArticleId IdType="pmc">PMC5443461</ArticleId><ArticleId IdType="pubmed">28490677</ArticleId></ArticleIdList></Reference><Reference><Citation>Goehring K.C., Marriage B.J., Oliver J.S., Wilder J.A., Barrett E.G., Buck R.H. Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2&#x2032;-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial. J. Nutr. 2016;146:2559&#x2013;2566. doi: 10.3945/jn.116.236919.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.116.236919</ArticleId><ArticleId IdType="pubmed">27798337</ArticleId></ArticleIdList></Reference><Reference><Citation>Noll A.J., Yu Y., Lasanajak Y., Duska-McEwen G., Buck R.H., Smith D.F., Cummings R.D. Human DC-SIGN binds specific human milk glycans. Biochem. J. 2016;473:1343&#x2013;1353. doi: 10.1042/BCJ20160046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160046</ArticleId><ArticleId IdType="pmc">PMC4875834</ArticleId><ArticleId IdType="pubmed">26976925</ArticleId></ArticleIdList></Reference><Reference><Citation>Newburg D.S., Tanritanir A.C., Chakrabarti S. Lactodifucotetraose, a human milk oligosaccharide, attenuates platelet function and inflammatory cytokine release. J. Thromb. Thrombolysis. 2016;42:46&#x2013;55. doi: 10.1007/s11239-015-1331-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1331-2</ArticleId><ArticleId IdType="pubmed">26743063</ArticleId></ArticleIdList></Reference><Reference><Citation>Atochina O., Daly-Engel T., Piskorska D., McGuire E., Harn D.A. A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism. J. Immunol. 2001;167:4293&#x2013;4302. doi: 10.4049/jimmunol.167.8.4293.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.8.4293</ArticleId><ArticleId IdType="pubmed">11591752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Kuang M., Li J., Zhu L., Jia Z., Guo X., Hu Y., Kong J., Yin H., Wang X., et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021;31:818&#x2013;820. doi: 10.1038/s41422-021-00495-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00495-9</ArticleId><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. Int. J. Mol. Sci. 2021;22:2108. doi: 10.3390/ijms22042108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22042108</ArticleId><ArticleId IdType="pmc">PMC7924650</ArticleId><ArticleId IdType="pubmed">33672738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik D., Bhandari R., Kuhad A. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. Expert Opin. Ther. Targets. 2021;25:491&#x2013;508. doi: 10.1080/14728222.2021.1918103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1918103</ArticleId><ArticleId IdType="pmc">PMC8095161</ArticleId><ArticleId IdType="pubmed">33857397</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirey K.A., Blanco J.C.G., Vogel S.N. Targeting TLR4 Signaling to Blunt Viral-Mediated Acute Lung Injury. Front. Immunol. 2021;12:705080. doi: 10.3389/fimmu.2021.705080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.705080</ArticleId><ArticleId IdType="pmc">PMC8285366</ArticleId><ArticleId IdType="pubmed">34282358</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Liu S., Leone S., Newburg D.S. Human colostrum oligosaccharides modulate major immunologic pathways of immature human intestine. Mucosal Immunol. 2014;7:1326&#x2013;1339. doi: 10.1038/mi.2014.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2014.20</ArticleId><ArticleId IdType="pmc">PMC4183735</ArticleId><ArticleId IdType="pubmed">24691111</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Liu S., Kling D.E., Leone S., Lawlor N.T., Huang Y., Feinberg S.B., Hill D.R., Newburg D.S. The human milk oligosaccharide 2&#x2032;-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. Gut. 2016;65:33&#x2013;46. doi: 10.1136/gutjnl-2014-307544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307544</ArticleId><ArticleId IdType="pubmed">25431457</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher H.D., Bode L., Tappenden K.A. Human Milk Oligosaccharides Influence Intestinal Epithelial Cell Maturation In Vitro. J. Pediatr. Gastroenterol. Nutr. 2017;64:296&#x2013;301. doi: 10.1097/MPG.0000000000001274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001274</ArticleId><ArticleId IdType="pubmed">28114245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chleilat F., Klancic T., Ma K., Schick A., Nettleton J.E., Reimer R.A. Human Milk Oligosaccharide Supplementation Affects Intestinal Barrier Function and Microbial Composition in the Gastrointestinal Tract of Young Sprague Dawley Rats. Nutrients. 2020;12:1532. doi: 10.3390/nu12051532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12051532</ArticleId><ArticleId IdType="pmc">PMC7284880</ArticleId><ArticleId IdType="pubmed">32466125</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Lozano S., Akkerman R., Beukema M., van Leeuwen S.S., Dijkhuizen L., de Vos P. 2&#x2032;-Fucosyllactose impacts the expression of mucus-related genes in goblet cells and maintains barrier function of gut epithelial cells. J. Funct. Foods. 2021;85:104630. doi: 10.1016/j.jff.2021.104630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jff.2021.104630</ArticleId></ArticleIdList></Reference><Reference><Citation>Newburg D.S., Ko J.S., Leone S., Nanthakumar N.N. Human Milk Oligosaccharides and Synthetic Galactosyloligosaccharides Contain 3&#x2032;-, 4-, and 6&#x2032;-Galactosyllactose and Attenuate Inflammation in Human T84, NCM-460, and H4 Cells and Intestinal Tissue Ex Vivo. J. Nutr. 2016;146:358&#x2013;367. doi: 10.3945/jn.115.220749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.115.220749</ArticleId><ArticleId IdType="pmc">PMC4725434</ArticleId><ArticleId IdType="pubmed">26701795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong C., Elderman M., Cheng L., de Haan B.J., Nauta A., de Vos P. Modulation of Intestinal Epithelial Glycocalyx Development by Human Milk Oligosaccharides and Non-Digestible Carbohydrates. Mol. Nutr. Food Res. 2019;63:e1900303. doi: 10.1002/mnfr.201900303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201900303</ArticleId><ArticleId IdType="pmc">PMC6771538</ArticleId><ArticleId IdType="pubmed">31140746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong C., Beukema M., Wang M., de Haan B.J., de Vos P. Human milk oligosaccharides and non-digestible carbohydrates prevent adhesion of specific pathogens via modulating glycosylation or inflammatory genes in intestinal epithelial cells. Food Funct. 2021;12:8100&#x2013;8119. doi: 10.1039/D1FO00872B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1FO00872B</ArticleId><ArticleId IdType="pubmed">34286788</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z.-T., Nanthakumar N.N., Newburg D.S. The Human Milk Oligosaccharide 2&#x2032;-Fucosyllactose Quenches Campylobacter jejuni-Induced Inflammation in Human Epithelial Cells HEp-2 and HT-29 and in Mouse Intestinal Mucosa. J. Nutr. 2016;146:1980&#x2013;1990. doi: 10.3945/jn.116.230706.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.116.230706</ArticleId><ArticleId IdType="pmc">PMC5037868</ArticleId><ArticleId IdType="pubmed">27629573</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi C.P., Wipf P., Yamaguchi Y., Fulton W.B., Kovler M., Ni&#xf1;o D.F., Zhou Q., Banfield E., Werts A.D., Ladd M.R., et al. The human milk oligosaccharides 2&#x2032;-fucosyllactose and 6&#x2032;-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling. Pediatr. Res. 2021;89:91&#x2013;101. doi: 10.1038/s41390-020-0852-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-020-0852-3</ArticleId><ArticleId IdType="pmc">PMC7529714</ArticleId><ArticleId IdType="pubmed">32221473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., He-Yang J., Tu W., Zhou X. Sialylated human milk oligosaccharides prevent intestinal inflammation by inhibiting toll like receptor 4/NLRP3 inflammasome pathway in necrotizing enterocolitis rats. Nutr. Metab. 2021;18:5. doi: 10.1186/s12986-020-00534-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-020-00534-z</ArticleId><ArticleId IdType="pmc">PMC7789326</ArticleId><ArticleId IdType="pubmed">33407596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehra S., Khambati I., Vierhout M., Mian M.F., Buck R., Forsythe P. Human Milk Oligosaccharides Attenuate Antigen-Antibody Complex Induced Chemokine Release from Human Intestinal Epithelial Cell Lines. J. Food Sci. 2018;83:499&#x2013;508. doi: 10.1111/1750-3841.14039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1750-3841.14039</ArticleId><ArticleId IdType="pubmed">29377120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong C., Cheng L., Krenning G., Fledderus J., de Haan B.J., Walvoort M.T.C., de Vos P. Human Milk Oligosaccharides Mediate the Crosstalk Between Intestinal Epithelial Caco-2 Cells and Lactobacillus plantarum WCFS1 in an In Vitro Model with Intestinal Peristaltic Shear Force. J. Nutr. 2020;150:2077&#x2013;2088. doi: 10.1093/jn/nxaa162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/nxaa162</ArticleId><ArticleId IdType="pmc">PMC7398781</ArticleId><ArticleId IdType="pubmed">32542361</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantscher-Krenn E., Zherebtsov M., Nissan C., Goth K., Guner Y.S., Naidu N., Choudhury B., Grishin A.V., Ford H.R., Bode L. The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats. Gut. 2012;61:1417&#x2013;1425. doi: 10.1136/gutjnl-2011-301404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2011-301404</ArticleId><ArticleId IdType="pmc">PMC3909680</ArticleId><ArticleId IdType="pubmed">22138535</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandelwal P., Andersen H., Romick-Rosendale L., Taggart C.B., Watanabe M., Lane A., Dandoy C.E., Lake K.E., Litts B.A., Morrow A.L., et al. A Pilot Study of Human Milk to Reduce Intestinal Inflammation After Bone Marrow Transplant. Breastfeed. Med. 2019;14:193&#x2013;202. doi: 10.1089/bfm.2018.0199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/bfm.2018.0199</ArticleId><ArticleId IdType="pubmed">30916575</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung T.C. The microbiota-immune axis as a central mediator of gut-brain communication. Neurobiol. Dis. 2020;136:104714. doi: 10.1016/j.nbd.2019.104714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104714</ArticleId><ArticleId IdType="pubmed">31846737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzetto L., Fava F., Tuohy K.M., Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex. J. Autoimmun. 2018;92:12&#x2013;34. doi: 10.1016/j.jaut.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.05.008</ArticleId><ArticleId IdType="pubmed">29861127</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith P.M., Howitt M.R., Panikov N., Michaud M., Gallini C.A., Bohlooly-Y M., Glickman J.N., Garrett W.S. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569&#x2013;573. doi: 10.1126/science.1241165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241165</ArticleId><ArticleId IdType="pmc">PMC3807819</ArticleId><ArticleId IdType="pubmed">23828891</ArticleId></ArticleIdList></Reference><Reference><Citation>Snelson M., de Pasquale C., Ekinci E.I., Coughlan M.T. Gut microbiome, prebiotics, intestinal permeability and diabetes complications. Best Pract. Res. Clin. Endocrinol. Metab. 2021;35:101507. doi: 10.1016/j.beem.2021.101507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2021.101507</ArticleId><ArticleId IdType="pubmed">33642218</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vadder F., Kovatcheva-Datchary P., Goncalves D., Vinera J., Zitoun C., Duchampt A., B&#xe4;ckhed F., Mithieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156:84&#x2013;96. doi: 10.1016/j.cell.2013.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.12.016</ArticleId><ArticleId IdType="pubmed">24412651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienenstock J., Kunze W., Forsythe P. Microbiota and the gut-brain axis. Nutr. Rev. 2015;73((Suppl. S1)):28&#x2013;31. doi: 10.1093/nutrit/nuv019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nutrit/nuv019</ArticleId><ArticleId IdType="pubmed">26175487</ArticleId></ArticleIdList></Reference><Reference><Citation>Magalh&#xe3;es N.S., Savino W., Silva P.M.R., Martins M.A., Carvalho V.F. Gut Microbiota Dysbiosis Is a Crucial Player for the Poor Outcomes for COVID-19 in Elderly, Diabetic and Hypertensive Patients. Front. Med. 2021;8:644751. doi: 10.3389/fmed.2021.644751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.644751</ArticleId><ArticleId IdType="pmc">PMC8385716</ArticleId><ArticleId IdType="pubmed">34458281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., Wan Y., Chung A.C.K., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159:944&#x2013;955.e8. doi: 10.1053/j.gastro.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., Guo F., Zhang X., Luo R., Huang C., et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin. Infect. Dis. 2020;71:2669&#x2013;2678. doi: 10.1093/cid/ciaa709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa709</ArticleId><ArticleId IdType="pmc">PMC7314193</ArticleId><ArticleId IdType="pubmed">32497191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H.-F., Li A., Zhang T., Ren Z.-G., He K.-X., Zhang H., Yang J.-Z., Luo Q.-X., Zhou K., Chen C.-L., et al. Disordered oropharyngeal microbial communities in H7N9 patients with or without secondary bacterial lung infection. Emerg. Microbes Infect. 2017;6:e112. doi: 10.1038/emi.2017.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2017.101</ArticleId><ArticleId IdType="pmc">PMC5750457</ArticleId><ArticleId IdType="pubmed">29259328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan P., Barreto J.N., Osmon D.R., Tosh P.K. Rothia bacteremia: A 10-year experience at Mayo Clinic, Rochester, Minnesota. J. Clin. Microbiol. 2014;52:3184&#x2013;3189. doi: 10.1128/JCM.01270-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01270-14</ArticleId><ArticleId IdType="pmc">PMC4313135</ArticleId><ArticleId IdType="pubmed">24951810</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel S., Mart&#xed;n R., Rossi O., Berm&#xfa;dez-Humar&#xe1;n L.G., Chatel J.M., Sokol H., Thomas M., Wells J.M., Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol. 2013;16:255&#x2013;261. doi: 10.1016/j.mib.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2013.06.003</ArticleId><ArticleId IdType="pubmed">23831042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.-R., Zhang Y.-N., Li X.-D., Zhang H.-Q., Xiao S.-Q., Deng F., Yuan Z.-M., Ye H.-Q., Zhang B. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Signal Transduct. Target. Ther. 2020;5:218. doi: 10.1038/s41392-020-00343-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00343-z</ArticleId><ArticleId IdType="pmc">PMC7532339</ArticleId><ArticleId IdType="pubmed">33011739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjanasirirat P., Suksatu A., Manopwisedjaroen S., Munyoo B., Tuchinda P., Jearawuttanakul K., Seemakhan S., Charoensutthivarakul S., Wongtrakoongate P., Rangkasenee N., et al. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci. Rep. 2020;10:19963. doi: 10.1038/s41598-020-77003-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77003-3</ArticleId><ArticleId IdType="pmc">PMC7672115</ArticleId><ArticleId IdType="pubmed">33203926</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa-Ngiamsuntorn K., Suksatu A., Pewkliang Y., Thongsri P., Kanjanasirirat P., Manopwisedjaroen S., Charoensutthivarakul S., Wongtrakoongate P., Pitiporn S., Chaopreecha J., et al. Anti-SARS-CoV-2 Activity of Andrographis paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives. J. Nat. Prod. 2021;84:1261&#x2013;1270. doi: 10.1021/acs.jnatprod.0c01324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jnatprod.0c01324</ArticleId><ArticleId IdType="pubmed">33844528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kongsomros S., Suksatu A., Kanjanasirirat P., Manopwisedjaroen S., Prasongtanakij S., Jearawuttanakul K., Borwornpinyo S., Hongeng S., Thitithanyanont A., Chutipongtanate S. Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. Biomedicines. 2021;9:1230. doi: 10.3390/biomedicines9091230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9091230</ArticleId><ArticleId IdType="pmc">PMC8465755</ArticleId><ArticleId IdType="pubmed">34572416</ArticleId></ArticleIdList></Reference><Reference><Citation>Goehring K.C., Kennedy A.D., Prieto P.A., Buck R.H. Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. PLoS ONE. 2014;9:e101692. doi: 10.1371/journal.pone.0101692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0101692</ArticleId><ArticleId IdType="pmc">PMC4085000</ArticleId><ArticleId IdType="pubmed">24999728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhaak L.R., Stroble C., Underwood M.A., Lebrilla C.B. Detection of milk oligosaccharides in plasma of infants. Anal. Bioanal. Chem. 2014;406:5775&#x2013;5784. doi: 10.1007/s00216-014-8025-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-014-8025-z</ArticleId><ArticleId IdType="pmc">PMC4157097</ArticleId><ArticleId IdType="pubmed">25059723</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez E., Santos-Fandila A., Buck R., Rueda R., Ramirez M. Major human milk oligosaccharides are absorbed into the systemic circulation after oral administration in rats. Br. J. Nutr. 2017;117:237&#x2013;247. doi: 10.1017/S0007114516004554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114516004554</ArticleId><ArticleId IdType="pubmed">28179042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Li T., Xie J., Zhang D., Pi C., Zhou L., Yang W. Gold standard for nutrition: A review of human milk oligosaccharide and its effects on infant gut microbiota. Microb. Cell Fact. 2021;20:108. doi: 10.1186/s12934-021-01599-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12934-021-01599-y</ArticleId><ArticleId IdType="pmc">PMC8162007</ArticleId><ArticleId IdType="pubmed">34049536</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Koningsbruggen-Rietschel S., Davies J.C., Pressler T., Fischer R., MacGregor G., Donaldson S.H., Smerud K., Meland N., Mortensen J., Fosb&#xf8;l M.&#xd8;., et al. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: A randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ Open Res. 2020;6:00132&#x2013;2020. doi: 10.1183/23120541.00132-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00132-2020</ArticleId><ArticleId IdType="pmc">PMC7569163</ArticleId><ArticleId IdType="pubmed">33123558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke W.-R., Chang R.Y.K., Kwok P.C.L., Chen D., Chan H.-K. Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs. Int. J. Pharm. 2020;591:119984. doi: 10.1016/j.ijpharm.2020.119984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119984</ArticleId><ArticleId IdType="pubmed">33069893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>